clinical mycology – Page 2

Clinical aspects and recent advances in fungal diseases impacting human health

mycolabadmin

Fungal infections affect over a billion people worldwide and are becoming harder to treat due to growing resistance to antifungal medications. The review discusses major challenges in detecting and treating these infections, including difficulty in diagnosis and limited awareness among healthcare providers. New antifungal drugs are being developed and approved to address these challenges, but a comprehensive approach involving better awareness, improved testing, and responsible medication use is needed.

Antifungal persistence: Clinical relevance and mechanisms

mycolabadmin

Some fungal infections don’t respond well to antifungal medications even though the fungi aren’t drug-resistant. This happens because a small percentage of fungal cells enter a dormant, low-energy state that protects them from being killed by the drugs. Understanding how these persistent cells survive and finding ways to target them could help prevent recurring fungal infections and improve treatment outcomes.

Onychomycosis in the US Pediatric Population—An Emphasis on Fusarium Onychomycosis

mycolabadmin

This study examined nail fungus infections in American children using advanced molecular testing. Researchers found that elementary school-aged children (ages 6-11) have the highest rates of nail fungus, usually caused by common fungi like Trichophyton rubrum. Notably, Fusarium, an environmental fungus that was once rare in nail infections, is becoming increasingly common, especially in older teenagers, which may require different treatment approaches.

Recent innovations and challenges in the treatment of fungal infections

mycolabadmin

Fungal infections are becoming more common and dangerous, especially for people with weakened immune systems, and many fungi are developing resistance to current medications. Doctors and researchers are developing new treatment strategies, including combining multiple drugs together and using advanced technologies to deliver medicines more effectively to infected areas. Natural compounds from plants and new biotechnology tools like genetic engineering and nanoparticles show promising results for fighting drug-resistant fungal infections.

John Perfect Shares Insights on Infectious Diseases, Antifungal Therapy, and Drug Resistance

mycolabadmin

This interview with Dr. John Perfect, a leading expert in fungal infections, discusses how antifungal treatments have evolved over his 48-year career. He explains that while fungal resistance is a concern, it’s less problematic than bacterial antibiotic resistance because fungi don’t spread resistance through plasmids. Dr. Perfect emphasizes the importance of newer, faster-acting antifungal drugs and combining drug therapy with immune system support to better treat serious fungal infections like cryptococcal meningitis and candidemia.

Performance of the VITEK® MS system for the identification of filamentous fungi in a microbiological laboratory in Chile

mycolabadmin

Researchers tested a fast machine called VITEK® MS for identifying dangerous mold infections in patients. The machine correctly identified over 91% of fungal samples, which is much better than waiting weeks for traditional laboratory methods. This technology could help doctors start treatment much faster for patients with serious mold infections, potentially saving lives.

ESCMID-EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

mycolabadmin

This survey examined how well hospitals in Belgium, the Netherlands, and Luxembourg can diagnose and treat serious fungal infections, which are particularly dangerous for people with weakened immune systems. The researchers found that while most hospitals can test fungal samples, not all have access to all necessary diagnostic tools, especially tests for detecting resistant fungi and identifying fungal co-infections. Many hospitals outsource their testing to other facilities, which can delay diagnosis and treatment, and some hospitals lack access to all recommended antifungal medications.

Aspergillus latus: A cryptic causative agent of aspergillosis emerging in Japan

mycolabadmin

Researchers in Japan discovered that a dangerous fungus called Aspergillus latus, previously unknown in the country, has been causing infections since at least 2013. This fungus is difficult to identify because it looks similar to other related species and is actually a hybrid created from two different Aspergillus species. The study found seven cases of this fungus in clinical samples and discovered that it is resistant to some common antifungal medications, making accurate identification crucial for proper patient treatment.

Multi-omics Analysis of Experimentally Evolved Candida auris Isolates Reveals Modulation of Sterols, Sphingolipids, and Oxidative Stress in Acquired Amphotericin B Resistance

mycolabadmin

Researchers studied how the fungus Candida auris develops resistance to amphotericin B, an important antifungal drug. By evolving two laboratory strains of this fungus under drug pressure, they discovered two different ways the fungus can become resistant: one through stress management genes, the other through changes in its protective lipids. These findings help explain why some clinical infections with this dangerous fungus are so hard to treat.

Data analysis of patients with positive mould or dimorphic fungal cultures from sterile sites

mycolabadmin

This study examined 48 patients with serious mould and fungal infections at a South African hospital between 2014-2017. Most infections occurred in people with weak immune systems, especially those with HIV. The most common fungal type was Aspergillus. Even with appropriate antifungal medicines, one-quarter of patients died, highlighting how serious these infections can be.

Research Keyword: clinical mycology